PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
13-Aug-2024 Venistro Biotech Highlights Key Trends Shaping the PCD Pharma Franchise Market for 2025-2032 Venistro Biotech
13-Aug-2024 What to Look for in a Trusted Itraconazole Capsules Manufacturer: Insights from Leading Pharma Manufacturer DM Pharma DM Pharma Private Limited
13-Aug-2024 Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study Eckert & Ziegler SE
13-Aug-2024 DEFENCE THERAPEUTICS COLLABORATION AGREEMENT WITH ORANO TO DEVELOP THE NEXT GENERATION OF TARGETED RADIO-IMMUNOTHERAPY FOR CANCER ADVANCES Defence Therapeutics Inc.
13-Aug-2024 Medios AG continues its growth trajectory in the first half of 2024 and records disproportionately high increase in earnings Medios AG
13-Aug-2024 Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb Evotec SE
13-Aug-2024 Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028 PolyPeptide Group
13-Aug-2024 Formycon reports a strong first half-year with multiple milestones achieved Formycon AG
12-Aug-2024 LAC Spotlights Brain Health Amid Growing Stress Concerns in Singapore, Features Brain-Boosting Supplements to Combat Damage From Stressors LAC Global
12-Aug-2024 Q&M Dental Group's profit after tax grew 84%, Board declared 0.40 cent interim dividend, a 150% increase over the same period last year Q&M Dental Group Ltd
09-Aug-2024 Subsidiaries of Vita 34 reach agreement with US licensor Vita 34 AG
09-Aug-2024 Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort Lantern Pharma
09-Aug-2024 Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024 Eckert & Ziegler SE
09-Aug-2024 APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed APONTIS PHARMA AG
09-Aug-2024 STRATEC POSTS RESULTS FOR FIRST HALF OF 2024 STRATEC SE
08-Aug-2024 Conference call on the results for the 3rd quarter 2023/24 (ending 30 June 2024) on 14 August 2024 Douglas AG
08-Aug-2024 PolyPeptide appoints Chief Commercial Officer PolyPeptide Group
08-Aug-2024  SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement SCHOTT Pharma AG & Co. KGaA
08-Aug-2024 Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update Immunic AG
08-Aug-2024 First half of 2024: RHÖN-KLINIKUM AG continues good business performance – outlook confirmed RHÖN-KLINIKUM Aktiengesellschaft